STOCK TITAN

Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) will conduct a conference call on December 9, 2020, at 10:00 a.m. ET to discuss clinical data from ongoing studies of eganelisib in triple-negative breast cancer (TNBC). This presentation coincides with the San Antonio Breast Cancer Symposium taking place virtually from December 8-11, 2020. Key presentations include initial data from the MARIO-3 phase II study and the ARC-2 study regarding combinations involving eganelisib and other treatments. More details and participation options are available on Infinity's website.

Positive
  • Scheduled a conference call to discuss clinical data, indicating ongoing research activity.
  • Presentation of initial data from MARIO-3 study highlights progress in TNBC treatment.
  • Involvement in multiple clinical studies showcases commitment to innovation.
Negative
  • None.

CAMBRIDGE, Mass.--()--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020.

Conference Call Information

A live webcast of the conference call can be accessed in the "Investors/Media" section of Infinity's website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2088322. An archived version of the webcast will be available on Infinity's website for 30 days.

Presentation Details:

Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

Presenter: Erika Hamilton, M.D., Tennessee Oncology

Date: Wednesday, December 9, 2020, 8:00 a.m. CT

Abstract: PS11-32

Poster Session: 11

Title: ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) ± eganelisib (IPI-549) in participants with metastatic ovarian and triple negative breast cancer

Date: Wednesday, December 9, 2020, 8:00 a.m. CT

Abstract: PS12-12

Poster Session: 12

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.

Tecentriq® is a registered trademark of Genentech, Inc.

Abraxane® is a registered trademark of Celgene.

Doxil® is a registered trademark of Janssen Products.

Contacts

Ashley Robinson
LifeSci Advisors, LLC
617-775-5956

FAQ

What is the purpose of Infinity Pharmaceuticals' conference call on December 9, 2020?

The conference call aims to discuss clinical data from ongoing studies of eganelisib in triple-negative breast cancer.

When will Infinity Pharmaceuticals present data on eganelisib at the San Antonio Breast Cancer Symposium?

Data will be presented on December 9, 2020, at 8:00 a.m. CT.

What studies will be discussed during Infinity Pharmaceuticals' conference call?

The call will cover initial data from the MARIO-3 and ARC-2 studies involving eganelisib.

Where can I access the conference call by Infinity Pharmaceuticals?

The conference call can be accessed via the 'Investors/Media' section on Infinity's website.

I:SPX Oct 2023 Weekly 3100.000

NASDAQ:INFI

INFI Rankings

INFI Latest News

INFI Stock Data

726.09k
81.91M
2.36%
23.49%
2.43%
Biotechnology
Healthcare
Link
United States
Cambridge